SynthesisAutoimmunity reviews2023
Development of systemic lupus erythematosus in patients with immune thrombocytopenic purpura: A systematic meta-analysis.
Synthesis in Autoimmunity reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Pooled it
- Development of ankylosing spondylitis in patients with ulcerative colitis: A systematic meta-analysis.PloS one · 2023Pooled it
- Unravelling the role of the non-coding RNAs PVT1/miR-181a in orchestrating IL-23/RORγt and FOXP3/IL-10 axes in thrombocytopenia associated with systemic lupus erythematosus: insights into the clinical paradox of antiphospholipid syndrome.Molecular biology reports · 2026Article
- Article
- Incidence of systemic lupus erythematosus in patients with immune thrombocytopenia: A nationwide study.British journal of haematology · 2026Article
- Prognostic Re-evaluation of Antinuclear Antibodies in Childhood Immune Thrombocytopenia.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Isolated thrombocytopenia as the initial manifestation of childhood-onset systemic lupus erythematosus: A case report.Medicine · 2025Article
- [Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- New-onset Systemic Lupus Erythematosus Manifestation Following COVID-19: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2024Review
- Possible immune mechanisms of gut microbiota and its metabolites in the occurrence and development of immune thrombocytopenia.Frontiers in microbiology · 2024Review
- A Case of Systemic Lupus Erythematosus (SLE)-Induced Immune Thrombocytopenia Presented With a Subdural Hematoma.Cureus · 2023Article
- Thrombocytopenia in Patients with Systemic Lupus Erythematosus.European journal of rheumatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundRecent population-based cohort studies suggest that the incidence of systemic lupus erythematosus (SLE) is increased in patients with immune thrombocytopenic purpura (ITP). We performed a systematic review and meta-analysis to evaluate the development of SLE in patients with ITP.
methodsLiterature search was performed in PubMed, Web of Science and Cochrane Library for studies published prior to October 2022. Studies were included that reported development of SLE in ITP patients. Forest plot was used to detect overall SLE frequency in ITP and compare risk ratios for SLE development in different ITP subgroups. Study heterogeneity was assessed by using I
results26 eligible studies comprising 14867 ITP patients were included in analysis. 311 ITP patients developed SLE during the follow-up period (range: 1.1-14 years) (2.09%, 95%CI: 1.87-2.33). Relative risk (RR) for developing SLE was significantly higher in female ITP patients (RR: 4.23, 95%CI: 2.52-7.12, p < 0.0001). Anti-nuclear antibody (ANA) was reported in 23 studies, there were 766/4377 ANA positive patients with ITP (17.5%). The risk of SLE development in ANA positive ITP patients was significant (RR: 26.29, 95%CI: 14.45-47.81, p < 0.0001).
conclusionsOur study suggests ITP patients are at high risk of developing SLE in future. Pooled data revealed that females and patients with a positive ANA titer are at a significantly high risk of developing SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.